Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Pharming Group N.V.NASDAQ: PHAR

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital dips below year-ago levels

Q1 FY2026 change in working capital of $114.41K fell 91.9% year over year, behind the +232.3% change in trailing-twelve-month change in working capital. Sequentially, it fell 95.0% from the prior quarter.

Context

  • Change in working capital amounted to 3.8% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -91.9% toward the trailing-twelve-month pace of +232.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$114.41K-95.0% QoQ
Last fiscal yearDec 2025
$14.4M+238.1% YoY
LTMMar 2026
$10.03M+232.3% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.9%——
1 year+238.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
14.4M USD
Year-over-year change
+238.1%

Change in Working Capital vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +232.3% is the 2nd highest of 9, against a peer median of +100.5%.
  • Change in working capital amounts to 2.7% of revenue for PHAR, versus a peer median of 47.6%.
PHAR Competitors
Change in Working Capital for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$160.4M USD+161.3%—16.7%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$71.66M USD-10.7%-1.2%7.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$52.13M USD+203.5%+11.0%78.9%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$20.93M USD+109.8%+4.1%0.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$15.28M USD+91.2%-27.6%47.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€10.48M EUR-2.6%+49.7%78.0%
PHARPharming Group N.V.LTM Mar 2026$10.03M USD+232.3%—2.7%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$9.99M USD+435.9%——
SLNSilence Therapeutics plcLTM Mar 2026$5.6M USD——607.2%
PHVSPharvaris N.V.LTM Sep 2026€2.93M EUR-56.1%-3.1%—
Peer median (excluding PHAR) —+100.5%+1.5%47.6%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.